A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Devalingam Mahalingam; Sanjay Goel; Santiago Aparo; Sukeshi Patel Arora; Nicole Noronha; Hue Tran; Romit Chakrabarty; Giovanni Selvaggi; Andres Gutierrez; Matthew Coffey; Steffan Nawrocki; Gerard Nuovo; Monica Mita

doi:10.3390/cancers10060160

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Devalingam Mahalingam
, Sanjay Goel
, Santiago Aparo
, Sukeshi Patel Arora
, Nicole Noronha
, Hue Tran
, Romit Chakrabarty
, Giovanni Selvaggi
, Andres Gutierrez
, Matthew Coffey
, Steffan Nawrocki
, Gerard Nuovo
, Monica Mita

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancers
Volume	10
DOIs	https://doi.org/10.3390/cancers10060160
State	Published - May 25 2018

Disciplines

Medicine and Health Sciences
Oncology
Immunology and Infectious Disease

Access to Document

10.3390/cancers10060160License: Unspecified

Cite this

@article{7b1bfbeceed74b39ac3b15daeac0dbc0,

title = "A Phase II Study of Pelareorep (REOLYSIN{\textregistered}) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma",

author = "Devalingam Mahalingam and Sanjay Goel and Santiago Aparo and Arora, \{Sukeshi Patel\} and Nicole Noronha and Hue Tran and Romit Chakrabarty and Giovanni Selvaggi and Andres Gutierrez and Matthew Coffey and Steffan Nawrocki and Gerard Nuovo and Monica Mita",

note = "Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of \textasciitilde{}18\% and 7\% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone ...",

year = "2018",

month = may,

day = "25",

doi = "10.3390/cancers10060160",

language = "American English",

volume = "10",

journal = "Cancers",

}

TY - JOUR

T1 - A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

AU - Mahalingam, Devalingam

AU - Goel, Sanjay

AU - Aparo, Santiago

AU - Arora, Sukeshi Patel

AU - Noronha, Nicole

AU - Tran, Hue

AU - Chakrabarty, Romit

AU - Selvaggi, Giovanni

AU - Gutierrez, Andres

AU - Coffey, Matthew

AU - Nawrocki, Steffan

AU - Nuovo, Gerard

AU - Mita, Monica

N1 - Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone ...

PY - 2018/5/25

Y1 - 2018/5/25

UR - https://pubmed.ncbi.nlm.nih.gov/29799479/

U2 - 10.3390/cancers10060160

DO - 10.3390/cancers10060160

M3 - Article

VL - 10

JO - Cancers

JF - Cancers

ER -

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Disciplines

Access to Document

Other files and links

Cite this